What are the adverse effects of Levophed (norepinephrine)?

Adverse Effects of Levophed (Norepinephrine)

Norepinephrine causes arrhythmias in 2-15% of patients, with additional risks including acute coronary events (1-4%), stroke (0.3-1.5%), limb ischemia (2%), and intestinal ischemia (0.6-4%). 1

Cardiovascular Adverse Effects

Arrhythmias (Most Common)

• Incidence: 2-15% of patients receiving norepinephrine 1
• Significantly lower than dopamine (25%) or epinephrine (15%) 1
• Risk increases with:
  • Profound hypoxia or hypercarbia 2
  • Concurrent use with cyclopropane or halothane anesthetics (generally contraindicated due to risk of ventricular tachycardia/fibrillation) 2
  • Underlying myocardial hypertrophy (may cause dynamic left ventricular outflow tract obstruction) 3

Acute Coronary Events

• Incidence: 1-4% across clinical trials 1
• Prevalence consistent with other vasopressors (vasopressin, angiotensin II, levosimendan)

Bradycardia

• Usually, norepinephrine's direct chronotropic effects are counterbalanced by vagal reflex activity from increased blood pressure, often resulting in heart rate decrease rather than increase 1
• However, paradoxical tachyarrhythmia can occur even at low doses in susceptible patients 4

Vascular and Ischemic Complications

Peripheral Ischemia

• Limb ischemia: 2% 1
• Intestinal ischemia: 0.6-4% 1
• Contraindicated in mesenteric or peripheral vascular thrombosis (increases ischemia and extends infarction area) unless life-saving 2

Extravasation from Peripheral IV

• Incidence: 2.3% when administered peripherally with protocol-based monitoring 5
• 75.8 events per 1,000 days of peripheral infusion 6
• Most extravasations cause minimal tissue injury when detected early 5, 6
• No cases of tissue necrosis or surgical intervention required in recent prospective studies using regular inspection protocols 5, 6

Cerebrovascular Events

• Stroke: 0.3-1.5% 1
• Central nervous system bleeding: ~1% in septic shock patients 1

Hypertensive Crisis

• Overdosage causes severe hypertension, headache, reflex bradycardia, marked peripheral resistance increase, and decreased cardiac output 2
• Management: discontinue infusion until blood pressure stabilizes 2

Critical Contraindications and Warnings

Absolute contraindication: Hypovolemic shock without concurrent volume resuscitation 2

• Continuous use without blood volume replacement causes:
  • Severe peripheral and visceral vasoconstriction
  • Decreased renal perfusion and urine output
  • Poor systemic blood flow despite "normal" blood pressure
  • Tissue hypoxia and lactate acidosis 2

Cardiac Effects (Variable)

• Effects on cardiac output are inconsistent and time-dependent 1
• May unmask myocardial depression with increased afterload 1
• Transient increases in stroke volume and coronary blood flow via β2-receptor stimulation 1
• Less arrhythmogenic than dopamine (RR 0.47 for supraventricular arrhythmias, RR 0.35 for ventricular arrhythmias) 7

Key Clinical Pitfalls

1. Do not use as sole therapy in hypovolemia - always ensure adequate volume resuscitation first 2
2. Avoid in patients on cyclopropane/halothane anesthesia - high risk of fatal arrhythmias 2
3. Monitor for dynamic LVOTO in patients with myocardial hypertrophy 3
4. Regular inspection of peripheral IV sites prevents serious extravasation injury 5, 6
5. High doses may compromise microcirculation despite achieving MAP targets - consider microcirculatory monitoring over rigid MAP goals 8